These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 37099643

  • 1. Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy.
    Kawahara Y, Kanazawa H, Takashio S, Tsuruta Y, Sumi H, Kiyama T, Kaneko S, Ito M, Hoshiyama T, Hirakawa K, Ishii M, Tabata N, Yamanaga K, Fujisue K, Hanatani S, Sueta D, Arima Y, Araki S, Usuku H, Nakamura T, Yamamoto E, Soejima H, Matsushita K, Kawano H, Tsujita K.
    Europace; 2023 May 19; 25(5):. PubMed ID: 37099643
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
    Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS.
    JACC Heart Fail; 2021 Feb 19; 9(2):115-123. PubMed ID: 33309574
    [Abstract] [Full Text] [Related]

  • 3. Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR-ACT.
    Nativi-Nicolau J, Judge DP, Hoffman JE, Gundapaneni B, Keohane D, Sultan MB, Grogan M.
    ESC Heart Fail; 2021 Oct 19; 8(5):3875-3884. PubMed ID: 34432383
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prevalence, Incidence, and Impact on Mortality of Conduction System Disease in Transthyretin Cardiac Amyloidosis.
    Donnellan E, Wazni OM, Saliba WI, Hanna M, Kanj M, Patel DR, Wilner B, Kochar A, Jaber WA.
    Am J Cardiol; 2020 Aug 01; 128():140-146. PubMed ID: 32650908
    [Abstract] [Full Text] [Related]

  • 7. Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: Distinct from wild-type transthyretin amyloidosis?
    Razvi Y, Ioannou A, Patel RK, Chacko L, Karia N, Riefolo M, Porcari A, Rauf MU, Starr N, Ganesananthan S, Blakeney I, Kaza N, Filisetti S, Bolhuis RE, Rowczenio D, Gilbertson J, Hutt D, Mahmood S, Lachmann HJ, Wechalekar AD, Kotecha T, Knight DS, Coghlan JG, Petrie A, Whelan CJ, Venneri L, Martinez-Naharro A, Hawkins P, Fontana M, Gillmore JD.
    Eur J Heart Fail; 2024 Feb 01; 26(2):383-393. PubMed ID: 37953725
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Ventricular arrhythmia burden and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis.
    Brown MT, Yalamanchili S, Evans ST, Ram P, Blank EA, Lyle MA, Merchant FM, Bhatt KN.
    Pacing Clin Electrophysiol; 2022 Apr 01; 45(4):443-451. PubMed ID: 35257420
    [Abstract] [Full Text] [Related]

  • 10. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.
    Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, Kataria S, Lohrmann G, Pipilas AR, Ruberg FL.
    Amyloid; 2022 Jun 01; 29(2):71-78. PubMed ID: 35083944
    [Abstract] [Full Text] [Related]

  • 11. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
    Maestro-Benedicto A, Vela P, de Frutos F, Mora N, Pomares A, Gonzalez-Vioque E, Briceño A, Cabrera E, Cobo-Marcos M, Dominguez F, Gonzalez-Lopez E, Segovia J, Lara-Pezzi E, Garcia-Pavia P.
    Eur J Heart Fail; 2022 Dec 01; 24(12):2367-2373. PubMed ID: 35999650
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
    Borne RT, Masoudi FA, Curtis JP, Zipse MM, Sandhu A, Hsu JC, Peterson PN.
    JAMA Netw Open; 2021 Jan 04; 4(1):e2035470. PubMed ID: 33496796
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
    Hayashi T, Fukamizu S, Hojo R, Komiyama K, Tanabe Y, Tejima T, Soejima K, Nishizaki M, Hiraoka M, Ako J, Momomura S, Sakurada H.
    Europace; 2013 Oct 04; 15(10):1507-15. PubMed ID: 23603305
    [Abstract] [Full Text] [Related]

  • 18. Need for pacing in patients who qualify for an implantable cardioverter-defibrillator: Clinical implications for the subcutaneous ICD.
    Kutyifa V, Rosero SZ, McNitt S, Polonsky B, Brown MW, Zareba W, Goldenberg I.
    Ann Noninvasive Electrocardiol; 2020 Jul 04; 25(4):e12744. PubMed ID: 31994819
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block.
    Cannie D, Patel K, Protonotarios A, Heenan I, Bakalakos A, Syrris P, Menezes L, Elliott PM.
    Open Heart; 2024 Mar 27; 11(1):. PubMed ID: 38538064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.